Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KURA
Previous Symbol
CUSIPN/A
Phone858-500-8800
Debt
Debt-to-Equity Ratio0.02
Current Ratio14.76
Quick Ratio10.22
Price-To-Earnings
Trailing P/E Ratio-7.63
Forward P/E Ratio-6.65
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.59 per share
Price / Book2.51
Profitability
EPS (Most Recent Fiscal Year)($1.52)
Net Income$-35,430,000.00
Net MarginsN/A
Return on Equity-44.83%
Return on Assets-39.47%
Miscellaneous
Employees32
Outstanding Shares38,040,000
Market Cap$456.06 million
OptionableOptionable
Kura Oncology (NASDAQ:KURA) Frequently Asked Questions
What is Kura Oncology's stock symbol?
Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."
How were Kura Oncology's earnings last quarter?
Kura Oncology Inc (NASDAQ:KURA) released its quarterly earnings results on Monday, November, 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.41) by $0.01. View Kura Oncology's Earnings History.
When is Kura Oncology's next earnings date?
What price target have analysts set for KURA?
7 brokers have issued 1-year price objectives for Kura Oncology's stock. Their predictions range from $19.00 to $35.00. On average, they anticipate Kura Oncology's share price to reach $28.8333 in the next twelve months. This suggests a possible upside of 150.7% from the stock's current price. View Analyst Price Targets for Kura Oncology.
What is the consensus analysts' recommendation for Kura Oncology?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kura Oncology.
What are Wall Street analysts saying about Kura Oncology stock?
Here are some recent quotes from research analysts about Kura Oncology stock:
- 1. According to Zacks Investment Research, "Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. " (11/9/2018)
- 2. Cann analysts commented, "The initiation of these potentially registration studies for tipifarnib is in-line with our expectations for timing. The initiation of in HRAS mutant HNSCC, following the recent positive data presented at 2018 ESMO, support our outlook for tipifarnib. The ESMO data compared favorably to the reference data in this setting and revealed an association between HRAS mutant allele frequency and objective response. We anticipate tipifarnib with launch in 2020 and grow to $1.85 billion in sales by 2022." (11/5/2018)
- 3. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating and $31 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Kura Oncology, Inc." (10/22/2018)
Has Kura Oncology been receiving favorable news coverage?
Media stories about KURA stock have been trending positive on Monday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kura Oncology earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Kura Oncology's key competitors?
Some companies that are related to Kura Oncology include Ironwood Pharmaceuticals (IRWD), Arena Pharmaceuticals (ARNA), Aimmune Therapeutics (AIMT), The Medicines (MDCO), AnaptysBio (ANAB), Opko Health (OPK), Cambrex (CBM), PTC Therapeutics (PTCT), G1 Therapeutics (GTHX), Innoviva (INVA), Endocyte (ECYT), Biohaven Pharmaceutical (BHVN), Corcept Therapeutics (CORT), Phibro Animal Health (PAHC) and Enanta Pharmaceuticals (ENTA).
Who are Kura Oncology's key executives?
Kura Oncology's management team includes the folowing people:
- Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 49)
- Dr. Antonio Gualberto, Head of Devel. & Chief Medical Officer (Age 53)
- Dr. Marc Grasso, CFO & Chief Bus. Officer
- Mr. John Farnam, Chief Operating Officer
- Dr. Yi Liu Ph.D., Chief Scientific Officer (Age 50)
Who are Kura Oncology's major shareholders?
Kura Oncology's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.30%), FMR LLC (6.01%), Eagle Asset Management Inc. (5.45%), Victory Capital Management Inc. (4.05%), Candriam Luxembourg S.C.A. (0.96%) and Bank of New York Mellon Corp (0.30%).
Which institutional investors are selling Kura Oncology stock?
KURA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Candriam Luxembourg S.C.A..
Which institutional investors are buying Kura Oncology stock?
KURA stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., BlackRock Inc., Victory Capital Management Inc., Alps Advisors Inc., WINTON GROUP Ltd, Wells Fargo & Company MN, Trexquant Investment LP and Bank of New York Mellon Corp.
How do I buy shares of Kura Oncology?
Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kura Oncology's stock price today?
One share of KURA stock can currently be purchased for approximately $11.50.
How big of a company is Kura Oncology?
Kura Oncology has a market capitalization of $456.06 million. The company earns $-35,430,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. Kura Oncology employs 32 workers across the globe.
What is Kura Oncology's official website?
How can I contact Kura Oncology?
Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]
MarketBeat Community Rating for Kura Oncology (NASDAQ KURA)
MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe KURA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days.
